

Early-Onset Neonatal Sepsis: A Continuing Problem in Need of Novel Prevention Strategies

Barbara J. Stoll, MD

Early-onset neonatal sepsis (EOS) remains a feared cause of severe illness and death among infants of all birthweights and gestational ages, with particular impact among preterm infants. Centers for Disease Control and Prevention investigators have studied the changing epidemiology of invasive EOS for several decades. The Active Bacterial Core surveillance (ABCs) network, a collaboration between the Centers for Disease Control and Prevention, state health departments, and universities, was established in 1995 to address emerging infectious diseases of public health importance, including infections due to major neonatal pathogens.^{1,2} ABCs data are remarkable because of the geographic distribution and size of the population-based network, laboratory-based identification of cases, linked epidemiologic and laboratory data, and surveillance over many years. In this issue of *Pediatrics*, Schrag and colleagues³ present ABCs data on the epidemiology of early-onset neonatal sepsis collected over a recent 10-year period, with special attention to group B streptococcal (GBS) and *Escherichia coli* infections.

Invasive GBS infection among neonates, identified in the 1960s,⁴ emerged as the most common cause of EOS, with high risk of morbidity and mortality. National guidelines for the prevention of perinatal GBS, first issued in 1996, recommended either antenatal screening for GBS colonization and intrapartum antimicrobial prophylaxis (IAP) for

colonized women or targeted IAP for women with obstetrical risk factors in labor known to increase GBS transmission.⁵ Revised guidelines in 2002 recommended universal antenatal screening for GBS at 35 to 37 weeks' gestational age to identify colonized women who should receive IAP.⁶ Guidelines were additionally refined in 2010 to provide neonatal management recommendations based on maternal risk factors and clinical condition of the infant at birth, with an attempt to reduce unnecessary evaluations of well-appearing infants without risk factors.⁷ Widespread adherence to national guidelines resulted in a remarkable decline in early onset GBS disease, but a concomitant increase in exposure to intrapartum antibiotics.⁸ Several studies have reported missed opportunities for GBS prevention.⁹ At the same time, clinicians and investigators voiced concerns about increased exposure to IAP with potential for an increase in non-GBS invasive pathogens and emergence of antibiotic resistance in GBS and other pathogens.

Schrag et al³ describe trends in EOS sepsis due to GBS and *E coli* and compare clinical and epidemiologic characteristics of these infections. Their findings once again document missed opportunities for GBS prevention; 37% of women with an indication did not receive IAP. The vast majority of neonates have bacteremia, with only a minority diagnosed with meningitis. Rates of EOS overall and of

H. Wayne Hightower Distinguished Professor in the Medical Sciences and Dean, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, Texas

Opinions expressed in these commentaries are those of the author and not necessarily those of the American Academy of Pediatrics or its Committees.

DOI: 10.1542/peds.2016-3038

Accepted for publication Sep 12, 2016

Address correspondence to Barbara J. Stoll, MD, McGovern Medical School, University of Texas Health Science Center at Houston, 6431 Fannin St, MSB G.150, Houston, TX 77030. E-mail: barbara.j.stoll@uth.tmc.edu

PEDIATRICS (ISSN Numbers: Print, 0031-4005; Online, 1098-4275).

Copyright © 2016 by the American Academy of Pediatrics

FINANCIAL DISCLOSURE: The author has indicated she has no financial relationships relative to this article to disclose.

FUNDING: No external funding.

POTENTIAL CONFLICT OF INTEREST: The author has indicated she has no potential conflicts of interest to disclose.

COMPANION PAPER: A companion to this article can be found online at www.pediatrics.org/cgi/doi/10.1542/peds.2016-2013.

To cite: Stoll BJ. Early-Onset Neonatal Sepsis: A Continuing Problem in Need of Novel Prevention Strategies. *Pediatrics*. 2016;138(6):e20163038

E coli are stable, with some continued decline in GBS, easing concerns about potential increase of *E coli* infection in the face of increased IAP. Although GBS remains the most common EOS pathogen overall, the relative incidence of GBS and *E coli* varied by state, with some states having more *E coli* than GBS cases for at least one of the years studied. Rates of infection, morbidity, and mortality continue to be highest among preterm, especially very low birth weight, infants and among black infants. Eleven percent of infected infants died. Although mortality was higher among very low birth weight infants infected with *E coli*, birth weight, pathogen, and mortality are interconnected. Although ABCs collects limited neonatal clinical information, 6% of survivors were reported to have sequelae at hospital discharge.

This study underscores the need for continued adherence to national GBS guidelines: universal antenatal screening and attention to the special cases of women in preterm labor who should be screened at delivery and women with presumed penicillin allergy. The identification of infants with possible EOS is based on obstetrical and neonatal risk factors and the condition of the infant at birth. In particular, evaluating the infant's condition is challenging and depends on clinical experience. The relative severity of clinical symptoms with different pathogens deserves additional study, especially because pathogen and neonatal complications may impact neurodevelopmental outcomes among survivors.¹⁰ Although not specifically addressed by this study, neonatal management of well-appearing term infants born to mothers with risk factors for infection, particularly chorioamnionitis, remains controversial. Risks of prolonged early neonatal antibiotics, including increases in late-onset sepsis, necrotizing enterocolitis, and death,^{11,12} as well as worrisome changes in the

microbiome,¹³ support efforts to prevent unnecessary therapy. The global epidemic of antimicrobial resistance demands continued surveillance of susceptibility patterns as well as evidence-based guidelines for antibiotic stewardship in high-risk newborns.

Unlike GBS, there are no evidence-based strategies to reduce the risk of early-onset Gram-negative infections, particularly *E coli*. Additional studies to delineate specific risk factors for non-GBS EOS might lead to novel preventive interventions. Maternal immunization against invasive pathogens could prevent disease in the triad of mother, fetus, and newborn, a worthy goal.¹⁴ GBS immunization would prevent both early- and late-onset neonatal disease and might have an impact on other adverse outcomes of pregnancy, including stillbirth, prematurity, and culture-negative clinical sepsis. More than 50 years after neonatal GBS was first described, it is time to see GBS vaccines in the clinical arena preventing disease in mothers and infants.

ABBREVIATIONS

ABC: Active Bacterial Core surveillance
 EOS: early-onset neonatal sepsis
 GBS: group B streptococcus
 IAP: intrapartum antimicrobial prophylaxis

REFERENCES

1. Langley G, Schaffner W, Farley MM, et al. Twenty years of active bacterial core surveillance. *Emerg Infect Dis*. 2015;21(9):1520–1528
2. Phares CR, Lynfield R, Farley MM, et al; Active Bacterial Core surveillance/Emerging Infections Program Network. Epidemiology of invasive group B streptococcal disease in the United States, 1999-2005. *JAMA*. 2008;299(17):2056–2065

3. Schrag SJ, Farley MM, Petit S, et al. Epidemiology of invasive early-onset neonatal sepsis, 2005 to 2014. *Pediatrics*. 2016;138(6):e20162013
4. Eickhoff TC, Klein JO, Daly AK, Ingall D, Finland M. Neonatal sepsis and other infections due to group B beta-hemolytic streptococci. *N Engl J Med*. 1964;271(24):1221–1228
5. Centers for Disease Control and Prevention. Prevention of perinatal group B streptococcal disease: a public health perspective. *MMWR Recomm Rep*. 1996;45(RR-7):1–24
6. Schrag S, Gorwitz R, Fultz-Butts K, Schuchat A. Prevention of perinatal group B streptococcal disease. Revised guidelines from CDC. *MMWR Recomm Rep*. 2002;51(RR-11):1–22
7. Verani JR, McGee L, Schrag SJ; Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC). Prevention of perinatal group B streptococcal disease—revised guidelines from CDC, 2010. *MMWR Recomm Rep*. 2010;59(RR-10):1–36
8. Schrag SJ, Verani JR. Intrapartum antibiotic prophylaxis for the prevention of perinatal group B streptococcal disease: experience in the United States and implications for a potential group B streptococcal vaccine. *Vaccine*. 2013;31(4 Suppl 4):D20–D26
9. Stoll BJ, Hansen NI, Sánchez PJ, et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Early onset neonatal sepsis: the burden of group B Streptococcal and *E. coli* disease continues. *Pediatrics*. 2011;127(5):817–826
10. Stoll BJ, Hansen NI, Adams-Chapman I, et al; National Institute of Child Health and Human Development Neonatal Research Network. Neurodevelopmental and growth impairment among extremely low-birth-weight infants with neonatal infection. *JAMA*. 2004;292(19):2357–2365
11. Cotten CM, Taylor S, Stoll B, et al; NICHD Neonatal Research Network. Prolonged duration of initial empirical antibiotic treatment is associated with increased

rates of necrotizing enterocolitis and death for extremely low birth weight infants. *Pediatrics*. 2009;123(1):58–66

12. Kuppala VS, Meinen-Derr J, Morrow AL, Schibler KR. Prolonged initial empirical antibiotic treatment is

associated with adverse outcomes in premature infants. *J Pediatr*. 2011;159(5):720–725

13. Langdon A, Crook N, Dantas G. The effects of antibiotics on the microbiome throughout development and alternative

approaches for therapeutic modulation. *Genome Med*. 2016;8(1):39

14. Nuccitelli A, Rinaudo CD, Maione D. Group B Streptococcus vaccine: state of the art. *Ther Adv Vaccines*. 2015;3(3):76–90

Early-Onset Neonatal Sepsis: A Continuing Problem in Need of Novel Prevention Strategies

Barbara J. Stoll

Pediatrics 2016;138;

DOI: 10.1542/peds.2016-3038 originally published online November 29, 2016;

Updated Information & Services

including high resolution figures, can be found at:
<http://pediatrics.aappublications.org/content/138/6/e20163038>

References

This article cites 14 articles, 3 of which you can access for free at:
<http://pediatrics.aappublications.org/content/138/6/e20163038#BIBL>

Subspecialty Collections

This article, along with others on similar topics, appears in the following collection(s):
Fetus/Newborn Infant
http://www.aappublications.org/cgi/collection/fetus:newborn_infant_sub
Neonatology
http://www.aappublications.org/cgi/collection/neonatology_sub
Infectious Disease
http://www.aappublications.org/cgi/collection/infectious_diseases_sub
Vaccine/Immunization
http://www.aappublications.org/cgi/collection/vaccine:immunization_sub

Permissions & Licensing

Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
<http://www.aappublications.org/site/misc/Permissions.xhtml>

Reprints

Information about ordering reprints can be found online:
<http://www.aappublications.org/site/misc/reprints.xhtml>

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN™



PEDIATRICS[®]

OFFICIAL JOURNAL OF THE AMERICAN ACADEMY OF PEDIATRICS

Early-Onset Neonatal Sepsis: A Continuing Problem in Need of Novel Prevention Strategies

Barbara J. Stoll

Pediatrics 2016;138;

DOI: 10.1542/peds.2016-3038 originally published online November 29, 2016;

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://pediatrics.aappublications.org/content/138/6/e20163038>

Pediatrics is the official journal of the American Academy of Pediatrics. A monthly publication, it has been published continuously since 1948. Pediatrics is owned, published, and trademarked by the American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk Grove Village, Illinois, 60007. Copyright © 2016 by the American Academy of Pediatrics. All rights reserved. Print ISSN: 1073-0397.

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN™

